Underutilization of Endovascular Therapy in Black Patients With Ischemic Stroke: An Analysis of State and Nationwide Cohorts
Adult
Male
Adolescent
Cardiology
610
Diseases
03 medical and health sciences
Signs and Symptoms
0302 clinical medicine
80 and over
Internal Medicine
Medical Specialties
Medicine and Health Sciences
Humans
Pathological Conditions
Aged
Ischemic Stroke
Retrospective Studies
Aged, 80 and over
Endovascular Procedures
Middle Aged
Texas
3. Good health
Black or African American
Cardiovascular Diseases
Geriatrics
Tissue Plasminogen Activator
Female
DOI:
10.1161/strokeaha.121.035714
Publication Date:
2022-01-24T10:00:10Z
AUTHORS (8)
ABSTRACT
Background and Purpose:
Endovascular therapy (EVT) is a very effective treatment but relies on specialized capabilities that are not available in every hospital where acute ischemic stroke is treated. Here, we assess whether access to and utilization of this therapy has extended uniformly across racial and ethnic groups.
Methods:
We conducted a retrospective, population-based study using the 2019 Texas Inpatient Public Use Data File. Acute ischemic stroke cases and EVT use were identified using the
International Classification of Diseases, Tenth Revision (ICD-10
) diagnosis and procedure codes. We examined EVT utilization by race/ethnicity and performed patient- and hospital-level analyses. To validate state-specific findings, we conducted patient-level analyses using the 2017 National Inpatient Sample for national estimates. To assess independent associations between race/ethnicity and EVT, multivariable modified Poisson regressions were fitted and adjusted relative risks were estimated accounting for patient risk factors and socioeconomic characteristics.
Results:
Among 40 814 acute ischemic stroke cases in Texas in 2019, 54% were White, 17% Black, and 21% Hispanic. Black patients had similar admissions to EVT-performing hospitals and greater admissions to comprehensive stroke centers (CSCs) compared with White patients (EVT 62% versus 62%,
P
=0.21; CSCs 45% versus 39%,
P
<0.001) but had lower EVT rates (4.1% versus 5.3%; adjusted relative risk, 0.76 [0.66–0.88];
P
<0.001). There were no differences in EVT rates between Hispanic and White patients. Lower rates of EVT among Black patients were consistent in the subgroup of patients who arrived in early time windows and received intravenous recombinant tissue-type plasminogen activator (adjusted relative risk, 0.77 [0.61–0.98];
P
=0.032) and the subgroup of those admitted to EVT-performing hospitals in both non-CSC (3.0% versus 5.5,
P
<0.001) and CSC hospitals (7.9% versus 10.4%,
P
<0.001) while there were no differences between Whites and Hispanic patients. Nationwide sample data confirmed this finding of lower utilization of EVT among Black patients (adjusted relative risk, 0.87 [0.77–0.98];
P
=0.024).
Conclusions:
We found no evidence of disparity in presentation to EVT-performing hospitals or CSCs; however, lower rates of EVT were observed in Black patients.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (33)
CITATIONS (17)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....